Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Alfa for Anemia of Cancer
NCT00091858Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2004
- Primary completion
- Oct 2006
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, randomised, double-blind trial in cancer-related anemia (CRA) comparing Darbepoetin Alfa with Placebo (2 arms). Primary endpoint: Occurrences of red blood cell transfusion. Started Apr 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
cancer-related anemia (CRA)
Beyond the preview
Go deeper on NCT00091858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091858.